Wave life sciences reports second quarter 2024 financial results and provides business update

Successful clinical translation of wave's rna medicines platform in hd patients with wve-003 provides further validation of wave's proprietary platform with pn and stereochemistry; opt-in package for wve-003 submitted to partner takeda and engagement with regulators initiated to discuss potential path to accelerated approval

WVE Ratings Summary

WVE Quant Ranking